Clinical significance of von Willebrand factor (vWF) combined with soluble fms-like tyrosine kinase 1 (sFlt-1) concentration in predicting the severity of acute pancreatitis

Clinical significance of von Willebrand factor (vWF) combined with soluble fms-like tyrosine kinase 1 (sFlt-1) concentration in predicting the severity of acute pancreatitis - VWF combined with sFlt-1 to predict the severity of acute pancreatitis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300067735

Enrollment

Unknown

Registered

2023-01-19

Start date

2023-01-23

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute pancreatitis

Interventions

Case series:no

Eligibility

Sex/Gender

All

Age

18 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1.The diagnosis of all patients should comply with the Atlanta Classification Standard (Revised Version) issued by the International Pancreatic Association in 2012 and at least two items in the AP diagnosis, as follows: (1) Acute and persistent abdominal pain; (2) The amylase activity in serum increased to more than 3 times of the upper limit of normal value; (3) Imaging examination showed that the pancreas had or had no morphological changes; 2.18-76 years old, male and female.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of pancreatitis or chronic pancreatitis; 2. Those with surgical indications; 3. Postoperative or ERCP secondary pancreatitis; 4. Those who have serious gastrointestinal diseases and cannot receive enteral nutrition; 5. Basic diseases such as severe diabetes, malignant tumor, blood disease, liver and kidney dysfunction, etc; 6. Those with abnormal mental behavior; 7. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Von Willebrand factor;Soluble fms-like tyrosine kinase 1;	—

Countries

China

Contacts

Public ContactZhang Zhizhong

Beijing Friendship Hospital, Capital Medical University

zhangzhizhongsx@163.com+86 15810146704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026